Clinical Trials Directory

Trials / Completed

CompletedNCT02284386

Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty

Evaluation of the Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Subjects Undergoing for Unilateral Total Knee Arthroplasty

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Pacira Pharmaceuticals, Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a Phase 4, multicenter, open-label study designed to characterize the pharmacokinetic (PK) profile of total bupivacaine in approximately 15 adult subjects undergoing primary unilateral total knee arthroplasty (TKA) with bupivacaine hydrochloride (HCl) spinal nerve block (SNB) and EXPAREL local infiltration into the surgical site.

Detailed description

On Day 1, following an epinephrine "wash" of the spinal block syringe, eligible subjects will receive a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure as a spinal block. EXPAREL 266 mg in 20 mL (expanded with 70 mL of preservative-free sterile normal saline to a total volume of 90 mL) will be infiltrated into the surgical site at the end of the surgery prior to wound closure. There will be no local co-administration of the two drugs. Blood samples for bupivacaine PK analysis will be obtained from subjects at baseline (prior to bupivacaine HCl administration for nerve block), 15 minutes, 30 minutes, and 1, 2, 4, 8, 12, 24, 48, and 72 hours after the beginning of EXPAREL administration, and on Day 14.

Conditions

Interventions

TypeNameDescription
DRUGBupivacaine SNBSNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
DRUGEXPAREL InfiltrationLocal infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.

Timeline

Start date
2014-12-01
Primary completion
2015-03-01
Completion
2015-03-01
First posted
2014-11-06
Last updated
2021-03-08
Results posted
2016-06-28

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02284386. Inclusion in this directory is not an endorsement.